Special Issue "Diagnostic Pathology of Breast Diseases"
Deadline for manuscript submissions: 29 February 2024 | Viewed by 591
Interests: breast pathology; gastrointestinal pathology; dermatopathology
Interests: herb-drug interactions; natural products; melanopsin; gentamicin; medicinal and pharmaceutical; physiology; cell culture; apoptosis; antioxidant activity; immunohistochemistry
Advances in genetics and molecular pathology in recent decades have led to the identification of different molecular subtypes of breast cancer. Newer findings, on which the new classification is based, made it possible to observe significant immunohistochemical and pathohistological differences between these entities that have the same embryonic origin. These tumors are defined both by their molecular phenotype and histopathological characteristics. However, histopathological classification remains the gold standard for diagnosis in most cases. Adequate pathological–radiological correlations of breast lesions, from mammography to ultrasound-guided core biopsies of the breast, are of particular importance. The use of monoclonal antibodies enabled the determination of hormone receptors, which is both therapeutically and prognostically significant. Given that breast cancers show hormonal regulation, both in the course of their genesis and in the course of their evolution, the determination of hormone receptors enables the adequate application of appropriate antihormonal therapy. The issue of discrepancies in immunohistochemical interpretation and the issue of standardized interpretation of reactivity on immunohistochemical preparations could be solved by quantitatively using photometric methods, where specifically stained regions are distinguished based on the color of the chromogen. Additionally, information on molecular prognostic and predictive markers is of great importance: regulators responsible for the repair of damaged DNA, regulators of cell migration and proliferation, regulators of apoptosis, as well as the effect of immune check point proteins (PDL1).
Dr. Ivan R. Ilić
Dr. Pavle Randjelovic
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- breast cancer
- triple-negative breast cancer
- ultrasound-guided breast core biopsy
- pathologic–radiologic correlation